iNOS Mediates High-Fat Diet-Associated Aggravation of Complete Freund's Adjuvant-Induced Inflammatory Pain.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE

Original Publication: Basel, Switzerland : MDPI, [2000-

Diet, High-Fat*/adverse effects ; Freund's Adjuvant*/adverse effects ; Nitric Oxide Synthase Type II*/metabolism ; Nitric Oxide Synthase Type II*/genetics ; Nitric Oxide Synthase Type II*/antagonists & inhibitors ; Inflammation*/chemically induced ; Inflammation*/metabolism ; Hyperalgesia*/metabolism ; Hyperalgesia*/etiology ; Pain*/metabolism ; Pain*/etiology ; Pain*/chemically induced; Animals ; Mice ; Male ; Mice, Inbred C57BL ; Disease Models, Animal

Chronic inflammatory pain (IP) remains a therapeutic challenge under the worldwide prevalence of the high-fat dietary lifestyle. This study aimed at identifying mediators of the IP augmented by short-term high-fat diet (HFD). IP was induced on C57BL/6J mice by unilateral, intra-plantar, injection of Complete Freund's Adjuvant (CFA). Von Frey test for mechanical hyperalgesia and Hargreaves' test for thermal hyperalgesia were performed at pre-injection baseline and post-injection 6th h. and days 1/3/5/7/10/14. Ad libitum HFD feeding started 2 weeks pre-injection in assigned groups. Body weight and random blood glucose levels were measured. RT-qPCR and ELISA helped quantify expression levels of the selected candidate genes at manipulated hind-paws. After CFA injection, at 1400 W, a highly selective inducible nitric oxide synthase (iNOS) inhibitor was administered regularly to elicit differences in CFA-induced pain behaviors and gene expression in HFD-fed mice. Results showed that HFD-fed mice were heavier (p < 0.001) and relatively hyperglycemic (p = 0.013) at baseline. HFD aggravated CFA-induced mechanical and thermal pain (mechanical: p = 0.0004, thermal: p = 0.003), showing prolonged hyperalgesic durations and reduced pain thresholds at multiple timepoints. HFD-influenced paws showed accentuated overexpression of pro-inflammatory cytokines and iNOS (RT-qPCR for IL-1β: p = 0.015, IL-6: p = 0.019, TNF: p = 0.04; ELISA for iNOS: p = 0.011). At 1400 W, exertion of analgesic effects (mechanical: p < 0.0001, thermal: p < 0.0001) but pro-inflammatory (RT-qPCR for IL-1β: p = 0.004, IL-6: p = 0.03, TNF: p = 0.04) were exerted on the inflamed paw on day 5 post-injection. In conclusion, short-term HFD aggravated CFA-induced inflammatory pain. Pharmacological inhibition of iNOS attenuated the CFA-induced pain in HFD-fed mice. Future research might uncover signaling pathways mediating such effects, potentially benefiting obese patients with chronic IP.

BMJ. 2014 Apr 15;348:g2272. (PMID: 24736206)
Brain Behav Immun. 2018 Nov;74:96-105. (PMID: 30071254)
Nutrients. 2020 Oct 26;12(11):. (PMID: 33114561)
Pain. 1993 Feb;52(2):127-136. (PMID: 8455960)
Tissue Cell. 2018 Jun;52:108-115. (PMID: 29857819)
Med J Aust. 2021 Apr;214(7):324-331. (PMID: 33786837)
Int J Mol Sci. 2016 Feb 18;17(2):249. (PMID: 26901193)
J Neurosci. 2000 Sep 1;20(17):6714-20. (PMID: 10964977)
Ann Intern Med. 2002 Feb 5;136(3):201-9. (PMID: 11827496)
J Steroid Biochem Mol Biol. 2014 Sep;143:444-50. (PMID: 25006014)
Nat Commun. 2020 Feb 4;11(1):698. (PMID: 32019928)
J Biophotonics. 2025 Feb;18(2):e202400398. (PMID: 39676335)
Arch Ital Urol Androl. 2013 Apr 19;85(1):36-40. (PMID: 23695404)
Sci Rep. 2017 Sep 4;7(1):10350. (PMID: 28871134)
Int J Mol Sci. 2023 Dec 04;24(23):. (PMID: 38069411)
Pharmaceuticals (Basel). 2024 Jan 16;17(1):. (PMID: 38256951)
Br J Pharmacol. 2023 Apr;180(7):975-993. (PMID: 34826881)
Curr Issues Mol Biol. 2024 Jan 19;46(1):842-855. (PMID: 38275668)
Biol Pharm Bull. 2009 Apr;32(4):553-7. (PMID: 19336883)
Rheumatology (Oxford). 2020 Jan 1;59(1):233-242. (PMID: 31298290)
Diabetes. 2004 Sep;53(9):2383-91. (PMID: 15331549)
J Pain. 2013 May;14(5):467-74. (PMID: 23499319)
Clin J Pain. 2019 Oct;35(10):818-825. (PMID: 31283548)
Signal Transduct Target Ther. 2023 May 22;8(1):207. (PMID: 37211559)
J Cell Mol Med. 2023 Aug;27(16):2340-2353. (PMID: 37329158)
Proc Natl Acad Sci U S A. 2014 May 20;111(20):7421-6. (PMID: 24799697)
Brain Behav Immun. 2019 Jul;79:284-293. (PMID: 30797044)
J Immunol. 2002 Jan 15;168(2):689-95. (PMID: 11777962)
J Med Chem. 2009 May 14;52(9):3047-62. (PMID: 19374401)
J Dent Res. 2015 Jan;94(1):129-39. (PMID: 25344334)
Sci Rep. 2017 May 11;7(1):1805. (PMID: 28496116)
Am J Clin Nutr. 2000 Jan;71(1 Suppl):179S-88S. (PMID: 10617969)
Physiol Res. 2020 Sep 30;69(Suppl 2):S273-S278. (PMID: 33094625)
J Clin Invest. 2012 Jan;122(1):153-62. (PMID: 22201683)
Nitric Oxide. 2011 Oct 30;25(3):243-54. (PMID: 21723953)
Sci Rep. 2025 Feb 13;15(1):5347. (PMID: 39948154)
Cells. 2023 Jul 22;12(14):. (PMID: 37508577)
Pharmacol Rev. 2005 Jun;57(2):217-52. (PMID: 15914468)
Pain. 2018 Sep;159(9):1731-1741. (PMID: 29708941)
NPJ Sci Food. 2023 Jul 17;7(1):35. (PMID: 37460765)
Curr Osteoporos Rep. 2018 Oct;16(5):603-610. (PMID: 30128836)
Naunyn Schmiedebergs Arch Pharmacol. 2021 Oct;394(10):2129-2139. (PMID: 34402957)
J Biochem. 2010 May;147(5):633-44. (PMID: 20053785)
J Neurosci Methods. 1994 Jul;53(1):55-63. (PMID: 7990513)
Neuropeptides. 2010 Apr;44(2):145-54. (PMID: 20045558)
Neural Regen Res. 2019 Nov;14(11):1870-1879. (PMID: 31290436)
Anesth Analg. 2009 Oct;109(4):1287-96. (PMID: 19762759)
Biochem Pharmacol. 2020 Jun;176:113862. (PMID: 32081790)
Curr Pain Headache Rep. 2012 Dec;16(6):509-17. (PMID: 23109051)
Am J Clin Nutr. 2011 May;93(5):950-62. (PMID: 21367944)
Int J Mol Sci. 2022 May 12;23(10):. (PMID: 35628240)
J Inflamm Res. 2020 Nov 10;13:883-895. (PMID: 33209047)
Inflamm Bowel Dis. 2014 Jul;20(7):1147-56. (PMID: 24859296)
Pain Physician. 2016 Nov-Dec;19(8):521-535. (PMID: 27906932)
Free Radic Biol Med. 2025 Apr;231:1-10. (PMID: 39978607)
Mol Ther. 2013 Feb;21(2):409-22. (PMID: 22929659)
Int J Cardiol. 2015 Nov 1;198:66-9. (PMID: 26151718)
Front Pain Res (Lausanne). 2023 Apr 11;4:1131069. (PMID: 37113211)
Biochim Biophys Acta Mol Basis Dis. 2022 Feb 1;1868(2):166315. (PMID: 34875367)
Hypertension. 1999 Dec;34(6):1237-41. (PMID: 10601124)
Br J Pharmacol. 2002 Jun;136(4):588-96. (PMID: 12055137)
Sci Signal. 2014 Nov 11;7(351):ra106. (PMID: 25389371)
Clin Orthop Relat Res. 2011 Nov;469(11):3172-80. (PMID: 21800208)
Curr Pharm Des. 2018 Feb 12;23(39):6071-6078. (PMID: 28619001)
Diabetol Metab Syndr. 2021 Mar 18;13(1):32. (PMID: 33736684)
BMC Complement Med Ther. 2020 Oct 7;20(1):302. (PMID: 33028307)
Pain. 2006 Jan;120(1-2):170-181. (PMID: 16360270)
J Ethnopharmacol. 2011 Mar 24;134(2):305-12. (PMID: 21182921)
Int J Mol Sci. 2023 Oct 13;24(20):. (PMID: 37894825)
J Pain. 2012 Jun;13(6):519-23. (PMID: 22543045)
Int J Mol Sci. 2015 Nov 18;16(11):27508-19. (PMID: 26593904)
Cancer Res. 2018 Apr 15;78(8):1948-1957. (PMID: 29431638)
Transplant Proc. 2015 May;47(4):1073-8. (PMID: 26036523)
Inflamm Res. 2007 Jan;56(1):32-7. (PMID: 17334668)
BMJ. 2021 Oct 12;375:n2321. (PMID: 34642179)
Commun Biol. 2022 Jan 11;5(1):26. (PMID: 35017640)
Pain. 1988 Jan;32(1):77-88. (PMID: 3340425)
Nature. 1988 Jun 16;333(6174):664-6. (PMID: 3131684)
Br J Nutr. 2006 May;95(5):947-54. (PMID: 16611385)
Circ Res. 2003 Jul 25;93(2):96-105. (PMID: 12881475)
Eur J Pharmacol. 2014 Sep 5;738:101-10. (PMID: 24726874)
Oncoimmunology. 2017 May 16;6(7):e1328338. (PMID: 28811968)
Ann Rheum Dis. 2024 Sep 30;83(10):1381-1388. (PMID: 38816064)
J Appl Physiol (1985). 2021 Aug 1;131(2):442-453. (PMID: 34138646)
Int J Biochem Cell Biol. 2008;40(11):2638-48. (PMID: 18599338)
Mediators Inflamm. 2023 Jun 8;2023:8821610. (PMID: 37332618)
Acta Anaesthesiol Scand. 2009 Oct;53(9):1107-20. (PMID: 19702699)
Ann N Y Acad Sci. 2018 Sep;1428(1):5-13. (PMID: 29806109)
Sci Rep. 2022 Sep 1;12(1):14840. (PMID: 36050326)
Endocr Metab Immune Disord Drug Targets. 2019;19(6):874-884. (PMID: 30760195)
J Dent Res. 2015 Sep;94(9):1286-94. (PMID: 26124217)
Arch Surg. 1997 Nov;132(11):1177-83. (PMID: 9366709)
Proc Natl Acad Sci U S A. 1993 Aug 1;90(15):7240-4. (PMID: 7688473)
Antioxidants (Basel). 2023 Jun 02;12(6):. (PMID: 37371936)
Sci Rep. 2018 Apr 23;8(1):6404. (PMID: 29686414)
Pain. 2021 Jun 1;162(6):1705-1721. (PMID: 33433146)
Br J Rheumatol. 1993 Jan;32(1):31-5. (PMID: 7678534)
Osteoarthritis Cartilage. 2018 Jul;26(7):978-987. (PMID: 29723636)
Adv Cancer Res. 2020;146:57-82. (PMID: 32241392)
J Cell Mol Med. 2009 Jun;13(6):1086-95. (PMID: 18429935)
Methods. 2001 Dec;25(4):402-8. (PMID: 11846609)
Neuroscience. 2024 May 24;547:98-107. (PMID: 38657727)
Braz J Med Biol Res. 2006 Nov;39(11):1425-34. (PMID: 17146555)
J Immunol. 1947 Oct;57(2):179-94. (PMID: 20266867)
Mol Pain. 2023 Jan-Dec;19:17448069231177634. (PMID: 37207346)
J Ethnopharmacol. 2025 Jan 13;339:119147. (PMID: 39592076)
Prog Mol Biol Transl Sci. 2015;131:1-30. (PMID: 25744668)
BMC Psychiatry. 2017 May 4;17(1):166. (PMID: 28472936)
PM R. 2020 Apr;12(4):410-419. (PMID: 31437355)
Arch Gen Psychiatry. 2003 Jan;60(1):39-47. (PMID: 12511171)
Proc Natl Acad Sci U S A. 2024 May 14;121(20):e2306776121. (PMID: 38709933)
Mol Pain. 2025 Jan-Dec;21:17448069251321339. (PMID: 39921559)
Br J Pharmacol. 2003 Apr;138(7):1351-7. (PMID: 12711636)
Microbiome. 2019 Jan 18;7(1):7. (PMID: 30658700)
Shock. 2023 Feb 1;59(2):200-213. (PMID: 36730767)
JAMA. 2019 Sep 24;322(12):1178-1187. (PMID: 31550032)
Inflamm Res. 2001 Feb;50(2):83-8. (PMID: 11289658)
J Physiol. 2023 Apr;601(8):1383-1405. (PMID: 36864773)
Clin Orthop Relat Res. 2025 May 1;483(5):939-951. (PMID: 39982019)
Ren Fail. 2009;31(8):704-10. (PMID: 19814638)
Clin Nutr Res. 2022 Apr 26;11(2):110-119. (PMID: 35559001)
Arthritis Res Ther. 2021 Mar 22;23(1):93. (PMID: 33752736)
Eur J Immunol. 2009 Apr;39(4):1019-24. (PMID: 19291698)
Arthritis Res Ther. 2011 Jun 16;13(3):R90. (PMID: 21679445)
Arthritis Rheum. 2012 Jul;64(7):2223-32. (PMID: 22246649)
Mediators Inflamm. 1997;6(1):3-21. (PMID: 18472828)
J Neurosci. 2023 Dec 13;43(50):8582-8595. (PMID: 37793910)
J Immunol. 2001 Jan 15;166(2):1169-77. (PMID: 11145698)
Diabetes. 2011 Oct;60(10):2474-83. (PMID: 21911747)
FASEB J. 2011 Mar;25(3):1088-96. (PMID: 21106937)
Signal Transduct Target Ther. 2024 Mar 4;9(1):53. (PMID: 38433280)

N.A. Peter Hung Professorship in Pain Research

Keywords: iNOS; inflammatory pain; obesity; short-term high-fat diet

9007-81-2 (Freund's Adjuvant)
EC 1.14.13.39 (Nitric Oxide Synthase Type II)
EC 1.14.13.39 (Nos2 protein, mouse)

Date Created: 20250613 Date Completed: 20250613 Latest Revision: 20250615

20260130

PMC12156260

10.3390/ijms26115422

40508229